Thrivent Financial for Lutherans’s Aldeyra Therapeutics ALDX Stock Holding History

Thrivent Financial for Lutherans’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-11,356	Closed	-$37K	–	2522
2024 Q1	$37K	Sell	11,356 -35,698	-76%	-$117K	﹤0.01%	2498
2023 Q4	$165K	Sell	47,054 -51,568	-52%	-$159K	﹤0.01%	2444
2023 Q3	$658K	Sell	98,622 -12,124	-11%	-$90K	﹤0.01%	1999
2023 Q2	$929K	Sell	110,746 -5,385	-5%	-$53.1K	﹤0.01%	1852
2023 Q1	$1.15M	Hold	116,131	–	–	﹤0.01%	1693
2022 Q4	$808K	Buy	116,131 +97,890	+537%	+$560K	﹤0.01%	1868
2022 Q3	$97K	Sell	18,241 -22,872	-56%	-$137K	﹤0.01%	2379
2022 Q2	$164K	Buy	+41,113	New	+$141K	﹤0.01%	2372

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Thrivent Financial for Lutherans's ALDX Position: Q2 2024 in Review

Thrivent Financial for Lutherans sold out of Aldeyra Therapeutics (ALDX) in Q2 2024, closing a stake of 11,356 shares — an estimated $37K sold.

Thrivent Financial for Lutherans first reported a position in ALDX in Q2 2022 and held it in 8 quarters. The position peaked at $1.15M in Q1 2023. 103 funds tracked by Wall St. Rank hold ALDX as of Q2 2024.

Thrivent Financial for Lutherans reported no remaining Aldeyra Therapeutics position as of Q2 2024 after selling out during the quarter.
Thrivent Financial for Lutherans sold 11,356 Aldeyra Therapeutics shares in Q2 2024, an estimated $37K.
Thrivent Financial for Lutherans first reported a position in Aldeyra Therapeutics in Q2 2022 and held it in 8 quarters.
Thrivent Financial for Lutherans's Aldeyra Therapeutics position peaked at $1.15M in Q1 2023.
103 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2024.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2024, filed 13 Aug 2024.